



March 16, 2021

FOR IMMEDIATE RELEASE

Company name Resorttrust, Inc.
Representative Ariyoshi Fushimi, President
Code 4681, First Section of the Tokyo and
 Nagoya Stock Exchanges

**Midtown Clinic and Toshiba have signed a Joint Research Agreement
on microRNA Detection Technology for Early Detection of Cancer
in the Tokyo Nihonbashi Medical Examination Course of the Grand HIMEDIC Club Tokyo**

Resorttrust, Inc. (“the Company”) hereby announces that today, Midtown Clinic Medical Corporation, which receives operational support from the Resorttrust Group, and HIMEDIC, Inc., a wholly owned subsidiary of the Company, entered into a joint research agreement with TOSHIBA CORPORATION (Minato-ku, Tokyo; “Toshiba”) for the purpose of conducting demonstration of a cancer detection technology that uses microRNAs¹ in blood. The development of this cancer detection technology was announced by Toshiba in November 2019.

Toshiba’s original microRNA detection technology was developed as part of a Japan Agency for Medical Research and Development (AMED) project, “Development of Diagnostic Technology for Detection of microRNA in Body Fluids*2,” that promoted key technologies and the discovery and manufacture of drugs for next-generation cancer diagnosis and treatment.

After further research and development that combined Toshiba’s technology and the advanced medical knowledge of Professor Takahiro Ochiya of the Department of Molecular and Cellular Medicine at the Institute of Medical Science, Tokyo Medical University and the National Cancer Center Japan, Toshiba announced the microRNA system on November 25, 2019. At the R&D level the system was found to be able to detect the presence of any of 13 different cancers, including pancreatic cancer and breast cancer, in only a few hours with 99% accuracy. In real-world application, it is expected to detect very early-stage cancers, including stage 0 cancers, and to realize same-day results by using Toshiba’s microRNA chip and compact, dedicated testing devices to reduce testing times.

The joint research between Toshiba and Midtown Clinic aims to verify the effectiveness of mi micro RNA detection technology for cancer screening by collecting approximately 1,000 samples and by leveraging the technologies and knowledge of both partners.

In addition, this joint research is scheduled to be validated at the Tokyo Nihonbashi Medical Examination Course of the Grand HIMEDIC Club Tokyo *3 operated by HIMEDIC, Inc by combining cancer screening using a combination of PET and other advanced examination equipment with microRNA detection technology, and Midtown Clinic plans to conduct verification.

Our entry to the medical business was prompted by identifying the needs concerning “health” through feedback from hotel members. In 1994, we became the first company in the world to introduce PET scanners for cancer screening at HIMEDIC Yamanakako Course. The outcomes of its research were reflected in the creation of cancer screening guidelines by the Japanese Society of Nuclear Medicine and contributed greatly to the popularization of PET in Japan and improvement of the rate of early detection of cancer.

While accumulating such results, we are also supporting the operation of clinics providing advanced cancer immunotherapy and high-precision radiotherapy, and expanding solutions from “detecting cancer” to “treating cancer.”

In November 2019, Cancer Intelligence Care Systems, Inc., a consolidated subsidiary of Resorttrust, Inc., and STELLA PHARMA CORPORATION, commenced a Phase I clinical trial of Boron Neutron Capture Therapy (BNCT) for malignant melanoma and angiosarcoma at the National Cancer Center Hospital of the National Cancer Center Japan.

These initiatives were made in the context of the Group’s vision, namely, “create a society where cancer claims no precious lives”—an aspiration that has guided its involvement in cancer screening and treatment. By combining the expertise we have cultivated thus far in integrated examination with microRNA detection technology, we will establish a new style of cancer screening and comprehensive solutions extending from early detection of cancer to early treatment.

■ About Midtown Clinic Medical Corporation “Nihonbashi Muromachi Mitsui Tower Midtown Clinic.”
Opened in May 2020 as a sister clinic of the Tokyo Midtown Clinic, which opened in Roppongi, Tokyo in 2007. In addition to undertaking medical examinations of the HIMEDIC Tokyo Nihonbashi medical examination course of the Grand HIMEDIC Club Tokyo, it also provides corporate health checks and general outpatient care, including internal medicine.

Chief Medical Director : Dr. Junichi Taguchi (Director, Grand HIMEDIC Club)

Director : Dr. Keisuke Hata



Nihonbashi Muromachi Mitsui Tower exterior
(7F : Nihonbashi Muromachi Mitsui Tower Midtown Clinic)



Reception



Private room

■ About Grand HIMEDIC Club

The Grand HIMEDIC Club Tokyo was born as part of Medical Operations of the Resort Trust Group, which operates luxury membership resorts and other services. It began providing the world's first cancer screening incorporating positron emission tomography (PET) at its Yamanakako Clinic in 1994. The medical examination system, which combines diagnostic imaging, such as PET, computed tomography (CT), and magnetic resonance imaging (MRI), with blood tests, is referred to as the Yamanakako System. The Club's membership exceeds 23,000, and there are currently eight medical examination courses nationwide with the opening of the HIMEDIC Tokyo Nihonbashi medical examination course in June 2020. The Club offers a wide range of services, including referrals to medical institutions in the event that an abnormality is detected in a medical examination, and daily health support services provided by the Club's doctors and medical concierges with nursing qualifications.

【Grand HIMEDIC Club website】

<https://www.himedic.jp/>

*1 microRNA

microRNA molecules, short nucleic acid molecules (consisting of about 20 bases) that regulate genes and proteins in the body, are known to be stable in blood. Examination of the types and quantity of microRNA in blood has recently been found to potentially enable early detection of various cancers, such as lung cancer and breast cancer. This discovery has triggered anticipation for microRNA as a novel diagnostic marker.

*2 “Development of Diagnostic Technology for Detection of microRNA in Body Fluids” project

A project conducted by the National Cancer Research Center in 2014-2018, that aimed to develop a new microRNA-based cancer detection system through comprehensive analysis of microRNA in patients' body fluids.

https://www.ncc.go.jp/jp/information/pr_release/2014/0613/index.html

*3 For the Tokyo Nihonbashi Medical Examination Course of the Grand HIMEDIC Club Tokyo members who wish to participate.

Acceptance will end as soon as the number of inspections reaches the upper limit.

This course is outsourced to the Nihonbashi Muromachi Mitsui Tower Midtown Clinic.